5-HT2A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: Involvement of the noradrenergic system

Experimental Brain Research

Volumn 226, Issue 2, 2013, Pages 285-295

  Quesseveur, G ^a   Reperant C ^a   David, D J ^a   Gardier, A M ^a   Sanchez, C ^b   Guiard, B P ^a  

^a University of Paris XI   (France)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

5 HT; 5 HT2A receptor; Antidepressants; Antipsychotics; Norepinephrine; SSRIs

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; DESIPRAMINE; ESCITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 2A RECEPTOR; VOLINANSERIN; ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; FORCED SWIMMING TEST; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; ADRENERGIC NERVE CELL; ANIMAL; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; TIME; DEFICIENCY; DRUG EFFECTS; TIME FACTOR;

ADRENERGIC NEURONS; ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MICE; MICE, KNOCKOUT; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 84879463300     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-013-3434-3     Document Type: Article

References (71)

1. Aghajanian GK, Vandermaelen CP (1982) Intracellular recording in vivo from serotonergic neurons in the rat dorsal raphe nucleus: methodological considerations. J Histochem Cytochem 30(8):813-814 (Pubitemid 13223738)
2. Baraban JM, Aghajanian GK (1980) Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 19(4):355-363 (Pubitemid 10095684)
3. Blier P, Blondeau C (2011) Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 128(Suppl 1):S3-S10. doi: 10.1016/S0165-0327(11)70003-9
4. Blier P, Szabo ST (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatr 66(Suppl 8):30-40 (Pubitemid 43004173)
5. Boothman LJ, Sharp T (2005) A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. NeuroReport 16(9):891-896 (Pubitemid 40904735)
6. Boothman LJ, Allers KA, Rasmussen K, Sharp T (2003) Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol 139(5):998-1004. doi: 10.1038/sj.bjp.0705328 (Pubitemid 36877398)
7. Bortolozzi A, Amargos-Bosch M, Adell A, Diaz-Mataix L, Serrats J, Pons S, Artigas F (2003) In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. Eur J Neurosci 18(5):1235-1246 (Pubitemid 37120471)
8. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M, Racagni G (2002) The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12(5):461-475
9. Cassano T, Gaetani S, Morgese MG, Macheda T, Laconca L, Dipasquale P, Taltavull J, Shippenberg TS, Cuomo V, Gobbi G (2009) Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res 34(8):1417-1426. doi: 10.1007/s11064-009-9928-5
10. Chen J, Gao K, Kemp DE (2011) Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatr 24(1):10-17. doi: 10.1097/YCO.0b013e3283413505
11. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS (2005) Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52(3):155-162. doi: 10.1159/000087847 (Pubitemid 41318195)
12. Cryan JF, Page ME, Lucki I (2002) Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436(3):197-205 (Pubitemid 34164699)
13. DeBattista C, Hawkins J (2009) Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23(5):369-377. doi: 10.2165/00023210-200923050-00002
14. Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (2011) The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther 17(6):723-732. doi: 10.1111/j.1755-5949.2010.00217.x
15. Denys D, Klompmakers AA, Westenberg HG (2004) Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology 176(2):195-203. doi: 10.1007/s00213-004-1880-0 (Pubitemid 39517949)
16. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121(1):66-72
17. Dremencov E, El Mansari M, Blier P (2007a) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatr 61(5):671-678. doi: 10.1016/j.biopsych.2006.05.015 (Pubitemid 46328857)
18. Dremencov E, El Mansari M, Blier P (2007b) Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 194(1):63-72. doi: 10.1007/s00213-007-0818-8 (Pubitemid 47282734)
19. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N (2005) Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30(7):1269-1277. doi: 10.1038/sj.npp.1300686 (Pubitemid 40848081)
20. Franberg O, Marcus MM, Svensson TH (2012) Involvement of 5-HT(2A) receptor and alpha(2)-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 66(7):650-660. doi: 10.1002/syn.21551
21. Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F (1996) Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10(1):16-27
22. Garratt JC, Kidd EJ, Wright IK, Marsden CA (1991) Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist. Eur J Pharmacol 199(3):349-355
23. Ghaemi SN, Katzow JJ (1999) The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatr 11(3):137-140 (Pubitemid 29420229)
24. Gobert A, Millan MJ (1999) Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38(2):315-317 (Pubitemid 29073553)
25. Guiard BP, El Mansari M, Merali Z, Blier P (2008) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11(5):625-639. doi: 10.1017/S1461145707008383 (Pubitemid 351931823)
26. Guiard BP, Mansari ME, Murphy DL, Blier P (2012) Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study. Int J Neuropsychopharmacol 15(3):349-361. doi: 10.1017/S1461145711000484
27. Hirose S, Ashby CR Jr (2002) An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatr 63(8):733-736
28. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR (2000) Comparative cytoarchitecture atlas of the C57BL/6 and 129/Sv mouse brains with CD ROM. Elsevier, San Diego
29. Holick KA, Lee DC, Hen R, Dulawa SC (2008) Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33(2):406-417. doi: 10.1038/sj.npp.1301399 (Pubitemid 350243341)
30. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY (2006) Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology 185(3):274-281. doi: 10.1007/s00213-005-0206-1
31. Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A (2009) 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatr Res 167(1-2):97-105. doi: 10.1016/j.psychres.2007. 12.012
32. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H, Nakamura J, Ozaki N, Iwata N (2010) HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med 12(3):237-242. doi: 10.1007/s12017-009-8105- y
33. Koch S, Perry KW, Bymaster FP (2004) Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46(2):232-242 (Pubitemid 37532831)
34. Li HF, Yu X, Yang K, He CY, Kou SJ, Cao SX, Xie GR (2012) The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorder. Genet Test Mol Biomarkers 16(7):667-671. doi: 10.1089/gtmb.2011.0232
35. Liu R, Jolas T, Aghajanian G (2000) Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 873(1):34-45 (Pubitemid 30468483)
36. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, Holsboer F, Domschke K (2010) HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 20(1):65-68. doi: 10.1016/j.euroneuro.2009.08.006
37. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N (2007) Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in vitro and in vivo studies. Int J Neuropsychopharmacol 10(1):31-40. doi: 10.1017/S1461145705006462 (Pubitemid 46122750)
38. Marek GJ, Aghajanian GK (1999) 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367(2-3):197-206 (Pubitemid 29106371)
39. Marek GJ, Martin-Ruiz R, Abo A, Artigas F (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30(12):2205-2215. doi: 10.1038/sj.npp.1300762 (Pubitemid 41643971)
40. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21(24):9856-9866 (Pubitemid 34184070)
41. Massou JM, Trichard C, Attar-Levy D, Feline A, Corruble E, Beaufils B, Martinot JL (1997) Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology 133(1):99-101 (Pubitemid 27395826)
42. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H (2006) Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78(5):804-814. doi: 10.1086/503820
43. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH (2001) The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatr 158(1):78-85 (Pubitemid 32047250)
44. Mongeau R, Blier P, de Montigny C (1997) The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev 23(3):145-195 (Pubitemid 27189731)
45. Nguyen HT, Guiard BP, Bacq A, David DJ, David I, Quesseveur G, Gautron S, Sanchez C, Gardier AM (2012) Blockade of the high-affinity norepinephrine transporter (NET) by the selective serotonin reuptake inhibitor escitalopram: an in vivo microdialysis study in mice. Br J Pharmacol. doi: 10.1111/j.1476-5381. 2012.01850.x
46. Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatr 60(4):256-259 (Pubitemid 29193925)
47. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147(2):162-167 (Pubitemid 30010563)
48. Pandey DK, Mahesh R, Kumar AA, Rao VS, Arjun M, Rajkumar R (2010) A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 94(3):363-373. doi: 10.1016/j.pbb.2009.09.018
49. Patel JG, Bartoszyk GD, Edwards E, Ashby CR Jr (2004) The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. Synapse 52(1):73-75. doi: 10.1002/syn.10308 (Pubitemid 38316272)
50. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP (2009) Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 19(1):1-10. doi: 10.1097/FPC.0b013e3283163ecd
51. Petit-Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 177(3):245-255. doi: 10.1007/s00213-004-2048-7 (Pubitemid 40137284)
52. Quesseveur G, Nguyen HT, Gardier AM, Guiard BP (2012) 5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs. doi: 10.1517/13543784.2012.719872
53. Rainer Q, Nguyen HT, Quesseveur G, Gardier AM, David DJ, Guiard BP (2012) Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol Pharmacol 81(2):106-112. doi: 10.1124/mol.111.075796
54. Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K (2004) Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatr 55(11):1103-1109. doi: 10.1016/j.biopsych.2004.02.012 (Pubitemid 38680563)
55. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatr 66(10):1289-1297 (Pubitemid 41546509)
56. Sibille E, Sarnyai Z, Benjamin D, Gal J, Baker H, Toth M (1997) Antisense inhibition of 5-hydroxytryptamine2a receptor induces an antidepressant-like effect in mice. Mol Pharmacol 52(6):1056-1063 (Pubitemid 28013724)
57. Sotty F, Folgering JH, Brennum LT, Hogg S, Mork A, Hertel P, Cremers TI (2009) Relevance of dorsal raphe nucleus firing in serotonin 5-HT(2C) receptor blockade-induced augmentation of SSRIs effects. Neuropharmacology 57(1):18-24. doi: 10.1016/j.neuropharm.2009.03.016
58. Szabo ST, Blier P (2001) Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 922(1):9-20 (Pubitemid 33152840)
59. Szabo ST, de Montigny C, Blier P (1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 126(3):568-571. doi: 10.1038/sj.bjp.0702343 (Pubitemid 29087832)
60. Szabo ST, de Montigny C, Blier P (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3(1):1-11. doi: 10.1017/S1461145700001772 (Pubitemid 30354447)
61. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374(6522):542-546. doi: 10.1038/374542a0
62. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dube S (2007) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatr 68(2):224-236 (Pubitemid 46362643)
63. Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289(1-2):109-119 (Pubitemid 14222511)
64. Viikki M, Huuhka K, Leinonen E, Illi A, Setala-Soikkeli E, Huuhka M, Mononen N, Lehtimaki T, Kampman O (2011) Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 501(1):20-24. doi: 10.1016/j.neulet.2011.06.031
65. Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon SC, Hen R, Gingrich JA (2006) Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313(5786):536-540. doi: 10.1126/science.1123432 (Pubitemid 44148461)
66. Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR (2009) Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9(1):61-70. doi: 10.1038/sj.tpj.6500491
67. Wright IK, Garratt JC, Marsden CA (1990) Effects of a selective 5-HT2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 99(2):221-222 (Pubitemid 20147508)
68. Xie H, Ma F, Zhang YQ, Gao X, Wu GC (2002) Expression of 5-HT(2A) receptor mRNA in some nuclei of brain stem enhanced in monoarthritic rats. Brain Res 954(1):94-99 (Pubitemid 35223445)
69. Zanardi R, Artigas F, Moresco R, Colombo C, Messa C, Gobbo C, Smeraldi E, Fazio F (2001) Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 21(1):53-58 (Pubitemid 32096750)
70. Zaniewska M, McCreary AC, Wydra K, Filip M (2010) Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology 58(7):1140-1146. doi: 10.1016/j.neuropharm.2010.02.006
71. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23(3):250-262. doi: 10.1016/S0893-133X(00)00119-6 (Pubitemid 30609659)